() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Cannvas.Me experiences record 524% increase in user engagement and on track for 50 million article views and 4 million unique visitors

Cannvas.Me experiences record 524% increase in user engagement and on track for 50 million article views and 4 million unique visitors

TORONTO, March 26, 2019 /CNW/ - Cannvas MedTech Inc. ("Cannvas" or the "Company") (CSE: MTEC) (Frankfurt: 3CM)  (OTCPK: CANVF), a leading digital cannabis education and analytics company, is pleased to announce unprecedented growth of its Cannvas.Me (www.cannvas.me) digital cannabis education platform as more global users from over 80 countries and 1,100 cities turn to Cannvas.Me for credible and evidence-based cannabis education. With user growth exceeding expectations and the platform's global reach expanding at a rapid pace, Cannvas.Me is poised to become the household name for cannabis education all while increasing its unique dataset to paint a clearer picture of cannabis consumption across Canada.



We are thrilled with our consistent new user acquisition and the way in which we keep existing users interested and engaged with Cannvas.Me, adding targeted new sections based on user needs including Cannvas For Her, Physician's Corner, our upcoming Athlete's Corner and much much more

said Shawn Moniz, Chief Executive Officer.

With so many visitors to Cannvas.Me in such a short period of time, it's clear not only Canadians, but the global audience of the 80 countries using our platform are starved for more in-depth evidence-based education on cannabis and understand that Cannvas has evolved into a trusted resource for physician-backed information on all aspects of the plant

Since the launch of Cannvas.Me in October, the educational platform has experienced a consistent month-to-month user growth of 30%, with a meteoric rise of 524% in March. The site is now on track to have over 4 million unique users accessing its free and unbiased cannabis education in 2019, with over 50 million views of Cannvas articles and courses before year's end.

This puts Cannvas on track to have over 90% of countries around the world engaging with its content before the end of 2019.

The average session duration for Cannvas.Me users has also increased month-to-month since the site's launch, up 10% each month in the past six months. With users spending an average of nearly 10 minutes on the site per visit.

Through a network of strategic partnerships focused on content and data sharing, coupled with a groundswell of global users looking to learn more about cannabis, Cannvas continues to outpace expectations as it surpasses growth projections

said Steve Loutskou, Chief Operating Officer, Global Markets.

We are thrilled with these results and expect our media and advertising partners to feel the same as their products and services are reaching more relevant audiences as our revenue streams continue to grow alongside our user base

The Company announced that it has issued a total of 38,000 common shares at a deemed price of $0.265 per common share to a service provider pursuant to a consulting agreement entered into with the service provider.

About Cannvas MedTech Inc.

Cannvas MedTech is a leading digital cannabis education and analytics company delivering accessible and evidence-based education while harnessing the power of data to paint a clearer picture of cannabis consumption across Canada.

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer's future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.  For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

SOURCE Cannvas MedTech Inc.


Comments are closed.